Palo Alto Investors LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Palo Alto Investors LP
CRD #109171
SEC #801-58166
CIK #0001012084, 0001306923
AUM 696.0 M (2026-03-27)
Employees 10 (40% Investors, 0% Brokers)
Fees
Minimum
Phone650-325-0772
Address101 University Ave
Palo Alto, CA 94301-1638
Source [IAPD] [EDGAR] [Website]
Total AUM ($B)
3.02.41.81.20.60.01999200820172027
Fees and Compensation — Form ADV Part 2A (3/27/2026) [Brochure]
Item 5.        Fees and Compensation

PAI’s compensation is negotiable and varies, and the investment advisory compensation
applicable to each Fund is set forth in detail in that Fund’s offering documents, except as otherwise
noted below with respect to the Sub-Advised Fund. A brief summary of those fees is described
below and typically consists of the following components:

                       First, PAI typically charges investors an annual fee of 1-1.5% of their assets
                   under management, depending on the fund in which they invest. Some current
                   investors who invested prior to May 1, 2008, pay an annual fee of 1.0%,
                   regardless of the Fund in which they invest. The management fee with respect
                   to each investor in a Fund is payable in advance in quarterly installments at the

                   beginning of each calendar quarter based on the net market value of the
                   investor’s assets on that date.

                       Second, PAI typically is allocated from each investor a performance
                   allocation equal to 20% of net profits (including both realized and unrealized
                   gains and losses) otherwise allocable to that investor.

Performance allocations are assessed in arrears on an annual basis (and on
withdrawals/redemptions) and are only applied to the portion of profits that exceed the cumulative
losses previously incurred by investors. Limited partners who joined a Fund before 1995 are
typically assessed a 15% performance allocation. PAI complies with Rule 205-3 under the
Investment Advisers Act of 1940, to the extent required by applicable law. Performance
allocations may create an incentive for PAI to make more risky and speculative investments than
it would otherwise make.

PAI typically deducts management fees and performance allocations directly from investor
accounts. Funds that invest in mutual funds or ETFs also pay, indirectly, investment advisory fees
to the managers of those funds.

PAI believes that its fees are competitive with fees charged by other investment advisers for
comparable services. Comparable services may be available, however, from other sources for
lower fees.

The disclosure in this Item 5, together with the disclosure in Item 12, allow a plan that is subject
to the Employee Retirement Income Security Act of 1974 and that invests in a Fund to use the
“alternative reporting option” to report PAI’s compensation as “eligible indirect compensation”
on Schedule C of the plan’s Form 5500 Annual Return/Report of Employee Benefit Plan.

An investor may withdraw part of its assets from most Funds as of any March 31 or September 30,
subject to a typical lockup of one to three years, as provided in the Fund’s partnership or investment
agreement. On any permitted withdrawal date for most PAI Funds, no more than 50% of an
investor’s assets may be withdrawn and the remainder may be withdrawn on the next permitted
withdrawal date, but if the remainder is not so withdrawn, then the withdrawal rights revert back
to the restriction that the next time a withdrawal occurs, no more than 50% of those assets may be
withdrawn and the remainder may be withdrawn on the next permitted withdrawal date.

An investor who withdraws from a Fund on a date other than the end of any quarter, as the case
may be, does not receive a refund of the management fee previously paid.

Each Fund is responsible for its own organizational, operational and investment costs and expenses,
as described in each Fund’s offering documents. PAI bears its own operating, general,
administrative and overhead costs and expenses. All or part of these costs and expenses may be
paid, however, by securities brokers that execute the Funds’ securities trades, as discussed in Item
12 below.

PAI also sub-advises a series of an unaffiliated Fund (the “Sub-Advised Fund”). The Sub-Advised
Fund is not charged a management fee but is subject to a 10% performance fee. PAI does not

deduct its fees from the Sub-Advised Fund’s account but instead the Sub-Advisor provides a
written payment notice to that Fund’s program manager. The Sub-Advised Fund can be terminated
on 60 days’ notice or sooner on certain “cause” events. The Sub-Advised Fund can withdraw from
its account at any time, although it is required to use its best efforts to notify PAI at least 30 days
before a withdrawal. Funds other than the Sub-Advised Fund are referred to in this brochure as
“PAI Funds.”

The Sub-Advised Fund is managed independently from PAI Funds and may have different
holdings, custodians, executing brokers, among other factors.
Account Minimums and Types of Clients — Form ADV Part 2A (3/27/2026) [Brochure]
Item 7.        Types of Clients

PAI provides investment advice to private pooled investment vehicles that are offered to investors
on a private placement basis. Investors in most PAI Funds generally are required to invest a
minimum of up to $1,000,000 depending on the Fund, but PAI may waive this minimum. Some
PAI Funds require a minimum investment of $250,000 or $5,000,000, but again, PAI may waive
this minimum.
Sector Form 13F Holdings Value ($B)
Insmed Inc 0.1
Acadia Pharmaceuticals Inc 0.1
PTC Therapeutics Inc 0.1
BioMarin Pharmaceutical Inc 0.0
United Therapeutics Corp 0.0
Anaptysbio Inc 0.0
Mirum Pharmaceuticals Inc 0.0
Dyne Therapeutics Inc 0.0
Biogen IDEC Inc 0.0
FS Development Corp 0.0
View All
Holdings by Sector ($B)
3.02.41.81.20.60.02011201620212027
Type Form D Funds Date Sold AUM
HF Palo Alto PE Fund LP [2015-05-15] 1.0 M 3.0 M
Filed 2026-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Lagunita LP [2015-02-26] 11.8 M 203.0 M
Filed 2020-03-31 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Palo Alto Micro Cap Liquidating Fund LP [2014-04-11] 2.9 M
Filed 2013-03-28 (D) · Exemption 506, 3(c), 3(c)(1) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Micro Cap Partners LP 2012-03-30 84.0 M
HF Palo Alto Advanced Life Sciences Master Fund LP [2012-03-30] 167.3 M 87.0 M
Filed 2026-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Palo Alto Crossover Fund LP 2012-03-30 0.1 M
HF Palo Alto Energy Master Fund LP 2012-03-30 13.0 M
HF Palo Alto Fund II LP 2012-03-30 6.0 M
HF Palo Alto Global Energy Liquidating Fund LP [2012-03-30] 8.3 M
Filed 2010-05-10 (D) · Exemption 506, 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Palo Alto Healthcare Master Fund II LP [2012-03-30] 228.4 M 280.0 M
Filed 2026-02-25 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 13 0.7
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 13 0.7
By Discretionary
Discretionary 13 0.7
Non-Discretionary 0 0.0
Total 13 0.7
By Non-United States Persons
Non-United States Persons 0.0
United States Persons 0.7
Total 13 0.7
Limited Partners2011 - 2026
State Board of Administration of Florida
Teachers' Retirement Security for Illinois Educators
Form D Directors Role # Filings # Firms 2011 - 2026
Ronan Guilfoyle Director 358 108
Roger Hanson Director 255 86
Cary Marr Director 115 33
Jonathan Roney Director 99 18
Scott Smith Executive Officer 105 4
Mark Shamia Executive Officer 14 4
Patrick Lee Director, Executive Officer 27 2
William Edwards Executive Officer 19 2
Palo Alto Investors LLC Executive Officer 16 2
Anthony Yun Executive Officer 16 2
View All
EDGAR Form CIK 2011 - 2026
3 [0001012084]
13F-HR [0001306923]
3 [0001306923]
4 [0001306923]
SC 13D [0001306923]
SC 13G [0001306923]
Form 13D/13G Filer Form 13D/13G Subject Filed
Palo Alto Investors LP Ehealth Inc [2026-02-17]
Palo Alto Investors LP Palo Alto Investors LP [2020-02-14]
Palo Alto Investors LP Aimmune Therapeutics Inc [2020-02-14]
Palo Alto Investors LLC Karyopharm Therapeutics Inc [2016-02-16]
Palo Alto Investors LLC Epizyme Inc [2016-02-16]
Palo Alto Investors LLC Sunesis Pharmaceuticals Inc [2016-02-16]
Palo Alto Investors LLC Clovis Oncology Inc [2015-02-18]
Palo Alto Investors LLC Insmed Inc [2015-02-18]
Palo Alto Investors LLC Staar Surgical Co [2015-02-18]
Palo Alto Investors LLC Clovis Oncology Inc [2015-02-18]
View All
Firm Profile (Form ADV)
Discretionary AUM$1.9B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
Form 3/4/5 Subject 2011 - 2026
Alimera Sciences Inc
Palo Alto Investors LP
Palo Alto Investors
Palo Alto Healthcare Master Fund LP
Palo Alto Healthcare Fund LP
Palo Alto Healthcare Fund II L P
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Alimera Sciences Inc ALIM
Common Stock
2023-03-24 Sell 200,919 $1.56 313,434
Alimera Sciences Inc ALIM
Series A Convertible Preferred Stock · derivative
2023-03-24 Sell 600,000 $1.56 936,000
Comparable Firms State AUM
Waystone Asset Management USA LLC
IL 742.6 M
Seneca Management LLC
CO 716.9 M
Olympus Peak Asset Management LP
CT 702.0 M
Maltese Capital Management LLC
NY 695.7 M
Newpoint Real Estate Investment Management LLC
NY 690.1 M
AW Jones Advisors LLC
NY 667.0 M
Archer Capital Group Management LLC
CA 659.6 M
M37 Management LP
CA 656.4 M
Altum Capital Management LLC
NY 647.8 M
Standard General LP
NY 647.3 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com